All In Biotech

Drug Trial Radar · NCT01073943

Investigation of PicoPrep Versus HalfLytely for Bowel Preparation for Colonoscopy - Day Before PicoPrep

A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety and Tolerability of "Day Before" PicoPrep™ for Oral Administration Versus HalfLytely® for Colon Cleansing in Preparation for Colonoscopy

Last checked: Nov 20, 2026Latest source record: Oct 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 603 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

603

Actual

Start

May 2010

Primary completion

Oct 2010

Study completion Oct 2010

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Feb 23, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Subjects undergoing an elective complete colonoscopy will randomly receive either PicoPrep: 2-sachets for oral solution in two divided doses given in the afternoon (first dose - sachet) and 6 hours later in the evening (second dose - sachet), given the day before the procedure or HalfLytely: for oral solution and two 5 mg Bisacodyl tablets, given the day before the procedure to evaluate its effectiveness, tolerability and safety.

Conditions

  • Bowel Preparation

Interventions

  • PicoPrepDrug

    PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.

  • HalfLytelyDrug

    HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.

  • bisacodylDrug

    Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded GastroenterologistTime frame: Day 2

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Florida Clinical Research Group

    Clearwater, Florida

  • Investigational site

    Hollywood, Florida

  • Nature Coast Clinical Research

    Inverness, Florida

  • Gastroenterology Associates, LLC

    Baton Rouge, Louisiana

  • Louisiana Research Center

    Shreveport, Louisiana

  • Investigative Clinical Research

    Annapolis, Maryland

  • NJ Physicians, LLC

    Passaic, New Jersey

  • Vital re:Search, Inc

    Greensboro, North Carolina

  • Gastroenterology Research Consultants of Greater Cincinnati

    Cincinnati, Ohio

  • Albert Einstein Medical Center

    Philadelphia, Pennsylvania

  • Gastroenterology Associates

    Kingsport, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.